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ABSTRACT 
ERIC SCOTT UBIL: p53 mediated mesenchymal-to-endothelial transition is a novel 
mechanism of vasculogenesis after ischemic cardiac injury 
(Under the direction of Arjun Deb) 
 
The mammalian heart displays limited regenerative capacity after acute ischemic 
injury and heals primarily through fibrosis.  Recent therapeutic research has focused on 
increasing vasculature at the site of injury as a means of preserving remaining myocardium 
and improving cardiac function after injury.  Other research has focused on the ability to 
reprogram cardiac fibroblasts using exogenous transcription factors to achieve a similar 
goal.  However, the ability of cardiac fibroblasts to adopt alternate cellular fates in the 
absence of exogenous factors is unclear. Here, we demonstrate that a subset of cardiac 
fibroblasts adopts the physiological and anatomical characteristics of native endothelial cells 
after ischemic cardiac injury in the absence of any added factors. Using mice harboring 
genetically labeled fibroblasts (Col1a2-CreERT:R26RtdTomato), we show that approximately 
30% of labeled cardiac fibroblasts in the injury border zone express endothelial markers 
such as VE-cadherin, eNOS, Occludin, and Claudin 5. Fibroblast derived endothelial cells 
comprised 25+/-2% of total luminal endothelial cells at the border zone 3 days after injury. 
To better understand fibroblast-endothelial transition we subjected cardiac fibroblasts to 
cellular stress (serum starvation) and found that they formed endothelium-like structures on 
Matrigel and up-regulated endothelial specific genes (e.g. VE-cadherin, Flk1, Flt1) 6-20 fold. 
We show that transition of fibroblasts to endothelial-like cells ex vivo is p53 dependent. 
Pharmacological inhibition of p53 using Pifithrin-α or genetic deletion in fibroblasts (Col1a2-
CreERT:p53fl/fl) led to a 94% mean decrease in Matrigel tube formation and 90% reduction 
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in endothelial gene expression.  Moreover, using semi-quantitative immunofluorescent 
staining, we observed that p53 levels in cardiac fibroblasts were more than 6 fold higher at 
the injury border zone.  Injection of a p53 activator, RITA, after injury doubled p53 levels in 
cardiac fibroblasts and increased the degree of mesenchymal-to-endothelial transition 
(MEndoT) by 43%. Enhanced MEndoT was also associated with decreased collagen 
deposition and improved heart function 7 days post injury. In summary, we show that 
cardiac fibroblasts adopt endothelial cell like fates after cardiac injury and contribute to the 
neovascularization of the injured region. Manipulation of MEndoT could represent a novel 
therapeutic strategy to increase post infarct angiogenesis and enhance function in the 
injured heart. 
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CHAPTER 1 Introduction 
 
Myocardial infarction and ischemia reperfusion injury 
 
Myocardial infarction, also known as heart attack, is the leading cause of morbidity 
and mortality in the United States. Each year, approximately 635,000 patients are diagnosed 
as having experienced a first myocardial infarction with another 280,000 experiencing a 
recurrent infarction1.   
During myocardial infarction, coronary blood flow is occluded, leading to the death of 
dependent downstream ventricular myocardium.  As the mammalian heart has limited 
regenerative capacity there is increased hemodynamic burden on the remaining 
cardiomyocytes, often leading to maladaptive remodeling in the heart and heart failure.  The 
heart heals primarily through fibrosis and scarring which are largely mediated by the cardiac 
fibroblast.  In the following sections an overview of cardiac fibroblasts and their roles in 
normal physiology and in the wound healing process will be described. 
 
Overview of cardiac fibroblasts 
Cardiac fibroblasts are the most populous type of cells in the heart and comprise 40-
60% of non-myocyte cells within the adult rodent heart2.  They are a highly heterogeneous 
population of cells that is spatially distributed throughout the heart3,4.  Morphologically, 
fibroblasts have been characterized as flat, spindle-shaped cells with numerous processes 
emanating from the main cell body5.   
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Cardiac fibroblasts reside within the myocardial interstitium and form a supportive 
stromal framework6.  They are also highly migratory and tend to form only weak attachments 
to the basement membrane and to neighboring cells7.   
Gene expression within the fibroblast population varies and is partially determined by 
the local environment7.  To date, a common expression marker has not been identified 
which can specifically label all of the subpopulations of cardiac fibroblasts.  Instead, 
research has mainly relied on the use of semi-specific markers to differentiate fibroblasts 
from other cell types.  As an example, expression of DDR2 has been commonly linked to 
cardiac fibroblasts though it is also expressed in fibrocytes and endothelial cells.  Similarly, 
Fsp1 expression has been used to identify cardiac fibroblasts but has also been 
demonstrated in various cancer cells.  Table 1.1 provides a summary of the most commonly 
used fibroblast markers and their expression in other cell types.  Lack of a commonly 
expressed fibroblast marker has been a significant challenge in the study of cardiac 
fibroblasts. 
 
Developmental origins of cardiac fibroblasts 
Cardiac fibroblasts are derived predominantly from the developing epicardium8,9.  
Cells from the emergent proepicardium migrate across the surface of the embryonic heart 
forming the epicardium, a single cell thick epithelial sheet covering the heart.  Cells derived 
from the epicardium, also known as Epicardially Derived cells (EPDCs), undergo Epithelial-
to-Mesenchymal Transition (EMT)10,11,12,13,14,15,16 in response to multiple growth factors such 
as PDGF, TGF, and FGF17.  After adopting a mesenchymal phenotype, the nascent 
fibroblasts invade the developing myocardium, which is facilitated by their lack of stable cell-
cell and cell-matrix adhesions.   
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Cardiac fibroblasts within the developing myocardium express extracellular matrix 
(ECM) proteins that govern the patterning of the developing heart.  The appropriate 
deposition and organization of ECM in the developing heart is particularly critical for 
electrical insulation of the atria from the ventricles18, in the patterning of the atrioventricular 
(AV) node5 and the annulus fibrosis18.  Within the endomysial network, fibroblasts also 
surround bundles of cardiomyocytes in a lamellar fashion and enable propagation of 
electrical activity along specific pathways19,20,21. 
 Unlike fibroblasts that reside within the myocardial interstitium, valvular fibroblasts 
are derived from endothelial cells within the developing cardiac cushion through a process 
termed Endothelial-to-Mesenchymal Transition (EndoMT).  In response to TGF-β, PDGF, 
and Wnt the endothelial cells delaminate, adopt a fibroblast phenotype and then invade the 
cardiac jelly and contribute to the formation of collagenous valve leaflets and the valve 
interstitium22,23. 
 
Fibroblast functions in normal physiological conditions 
 Cardiac fibroblasts are known to play two key roles in basal physiological conditions 
which will be described in the following sections.  First, fibroblasts maintain the ECM 
framework of the heart.  Secondly, fibroblasts help to regulate electrical circuits within the 
heart.  Both functions are critical to the continuous regulated beating in the healthy heart. 
Cardiac fibroblasts provide the structural framework of the heart 
During basal heart function, cardiac fibroblasts provide the three dimensional 
extracellular matrix (ECM) scaffolding for the various cell types within the heart.  The 
scaffold provides the structural framework of the heart, distributing mechanical force 
throughout the tissue and providing attachment points for the all the other cell types that 
reside there5.   
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The ECM is maintained by cardiac fibroblasts through a homeostatic balance of 
synthesis and degradation of numerous collagens, glycoproteins, and proteoglycans24,25.  
One of the key components of the ECM is fibrillar collagen, which when cross-linked 
provides tensile strength.  Roughly 90% of the collagens found in the heart are types I and 
III.  To a lesser extent, fibroblasts also secrete collagen types IV, V, and VI as well as elastin 
and laminin26. 
To maintain homeostatic balance, fibroblasts also degrade the ECM by secretion of 
matrix metalloproteinases (MMPs).  MMPs are a family of zinc dependent proteinases that 
degrade collagen and other components of the ECM.  Fibroblasts can further control MMP 
mediated degradation of the ECM through the secretion of tissue inhibitors of 
metalloproteinases (TIMPs), which can effectively block the activity of MMPs27. 
 
Cardiac fibroblasts provide electrical insulation and electrical coupling of 
cardiomyocytes 
 In addition to providing the scaffold for the heart, the ECM also serves to insulate 
groups of myocytes, allowing electrical separation and differential contraction of the heart 
chambers.  This property allows the regulated sequential beating of various parts of the 
heart, as seen in the electrical separation of the atria and ventricles by the annulus fibrosis, 
allowing asynchronous cardiac contraction28. 
 A subset of cardiac fibroblasts has also been demonstrated to play a more direct role 
in the electrophysiology of the heart.  Through gap junctions with myocytes, mediated by 
connexins 40, 43, and 4529,30,31,32, fibroblasts can facilitate electrical signal transduction and 
link cardiomyocytes that would otherwise be electrically insulated by the ECM.  Fibroblasts 
are non-excitable cells with high membrane resistance, which makes them good conductors 
of electrical signals5. 
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Roles of fibroblasts after cardiac injury 
After cardiac injury, the fibroblast is one of the primary effectors of fibrotic wound 
healing and scarring.  As described in this section, the cardiac fibroblast communicates with 
other cell types to mediate the progression of wound healing in the context of the injured 
site. 
Within the first 24 hours after cardiac injury, the injured region is infiltrated by a 
polymorphonuclear infiltrate.  Over the next 48 hours inflammatory cells, such as monocytes 
and macrophages, replace the polymorphonuclear infiltrate and facilitate apoptosis and 
phagocytosis of necrotic cells6,33.  Macrophages also express several growth factors, such 
as PDGF34, TNFa35, IL-1 and IL-636; that induce proliferation and migration of resident 
fibroblasts as well as localization of circulating cells, which leads to an increase in the 
number of fibroblasts and myofibroblasts at the site of injury.   
After injury, macrophages also secrete pro-angiogenic stimuli such as VEGF37.  As 
the macrophage population declines, activated cardiac fibroblasts take over as key 
expressors of pro-angiogeneic cytokines and regulators of endothelial cell proliferation38,39. 
This pro-angiogenic effect of cardiac fibroblasts is an important repair response and leads to 
the formation of the fibroblast and endothelium rich granulation tissue, an early stage of the 
fibrotic scar.   
 During granulation tissue formation, fibroblasts continue to proliferate and migrate 
from other areas of the heart in response to chemotactic ques.  They also increase collagen 
deposition at the injury border zone and progressively migrate towards the center of in the 
infarct site33.  In the early stages of wound healing (i.e. within 3 days), fibroblasts primarily 
secrete Type III collagen but switch to Type I collagen as wound healing progresses40.  
Cross-linked Type I collagen confers tensile strength to the wound site which helps to 
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prevent excess infarct site expansion and reduces the chances of cardiac rupture from 
increased hemodynamic burden41. 
 As wound healing progresses, there is increased activation of fibroblasts to adopt a 
myofibroblast phenotype.  The contractile properties of the myofibroblast foster wound 
contraction and remodeling of the ECM to form the mature scar.  ECM remodeling takes 
place partly through the degradation of collagen fibers, which occurs after a half-life of 
approximately 80-120 days and is mediated by zinc-dependent MMPs including 
collagenases and gelatinases42.   
During the remodeling process, fibroblasts and endothelial cells reach their peak 
numbers  at approximately 7 days after injury43 and then begin to decline as the scar 
matures, leaving a largely acellular scar44.    In the mature scar, ECM can occupy as much 
as 80% of the infarct area41.  The scar tends to persist, and populations of myofibroblasts 
which maintain the scar have been observed at the site of injury as long as 20 years later45.   
 
Fibroblast adoption of the myofibroblast phenotype after injury 
 Myofibroblasts are present after cardiac injury but not before46.  They are a 
specialized cell type with the migratory and ECM secretory characteristics of fibroblasts but 
are also capable of exerting contractile forces.  Myofibroblasts can be distinguished from 
fibroblasts in their expression of alpha-Smooth Muscle Actin (αSMA)33.  Myofibroblasts also 
differ from smooth muscle cells, which express αSMA, by their fibroblast characteristics and 
by their relatively lower expression of smooth muscle myosin heavy chain33. 
After injury, myofibroblasts are derived from a number of diverse sources including 
resident fibroblasts, endothelial cells (through EndoMT)47, epithelial cells (through EMT)48, 
mesenchymal stem cells (MSCs)49, smooth muscle cells49, and pericytes50,51.  Circulating 
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fibrocytes52, which are a distinct population of leukocytes with characteristics of fibroblasts, 
and a subpopulation of monocytes that coexpress monocytic markers (i.e. CD45 and 
CD11b) and myofibroblast markers (i.e. Fsp1 and αSMA) have also been shown to 
contribute to the myofibroblast population53.  The relative contribution of each source to the 
myofibroblast pool after injury varies by study and to date the relative contribution of each 
source has yet to be fully delineated. 
The conversion of fibroblasts to myofibroblasts is thought to take place through an 
intermediate phenotype known as the proto-myofibroblast.  Fibroblasts exposed to 
increased mechanical stress by post-injury disruption of the ECM framework or PDGF will 
adopt the intermediate state46.  Proto-myofibroblasts can then be induced to adopt a 
myofibroblast fate by exposure to TGF-β or Fibronectin Extra Domain A splice variant (FN-
ED-A)46.  TGF-β is primarily secreted by fibroblasts, and provides chemotactic cues to 
migratory myofibroblasts, attracting them to the site of injury33.  Inflammatory cells such as 
macrophages, T cells and mast cells have the ability to negatively regulate the effects of 
TGF-β activation by expression of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, and TGF-
α), which can inhibit the adoption of the myofibroblast state54. 
 After the adoption of the myofibroblast phenotype, the contractile properties of the 
cells facilitate the scar compaction typical in maturing scars.  The contractility of 
myofibroblasts is partially regulated by factors such as TGF-β1, relaxin, and angiotensin 
II5,33.  Interestingly, cardiomyocytes can effectively produce angiotensin and locally regulate 
myofibroblast contractility. 
Scar compaction and remodeling of the ECM leads to the formation of a dense and 
well organized scar with increased tensile properties.  The contractile actions of the 
myofibroblasts have also been proposed to slow adverse cardiac remodeling by preventing 
infarct expansion and ventricular dilation which would otherwise lead to wall thinning and 
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cardiomyocyte hypertrophy33.  Interference with myofibroblast recruitment and contractility 
has been demonstrated to negatively affect cardiac remodeling after injury33.   
 
Endothelial-to-Mesenchymal Transition 
 
 The cardiac fibroblast serves a number of roles before injury and is essential to 
cardiac repair after injury.  Endothelial-to-Mesenchymal Transition, or EndMT, has been 
described as a source of fibroblasts and myofibroblasts after injury.  In a murine trans-aortic 
constriction (TAC) model of chronic high blood pressure, Zeisberg and colleagues used 
lineage tracing to determine that genetically labeled endothelial cells adopt a fibroblast 
phenotype in response to chronic injury5547.  This novel finding demonstrated that cellular 
plasticity exists between endothelial cells and fibroblasts and has since been confirmed by 
several other groups56,57,58,59,60. 
 Prior to injury, endothelial cells comprise the lining of the blood vessel lumen61.  
Morphologically, they are flat cells that use mechanosensory cues to align with directional 
blood flow62.  Endothelial cells differ from fibroblasts in their ability to form strong intercellular 
junctions, such as adherens and tight junctions, which create a selective barrier to blood 
flow and preclude endothelial cells from having migratory traits63. 
 Given the cellular plasticity that has been demonstrated by endothelial cells after 
chronic cardiac injury via EndMT, it led us to question whether ischemic cardiac injury could 
trigger fibroblasts to undergo the reverse process, which we have termed Mesenchymal-to-
Endothelial Transition (MEndoT), and adopt an endothelial phenotype. 
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RESEARCH PRESENTED IN THIS DISSERTATION 
 
As described in the following chapter summaries, the goals of this dissertation thesis are: 
Chapter 2. To determine whether cardiac fibroblasts undergo MEndoT after injury 
Angiogenesis and the restoration of blood flow to the ischemic area are essential to 
continued wound healing after cardiac injury.  My data demonstrates that in addition to the 
previously described role of secretion of pro-angiogenic factors during scar formation, a 
subset of cardiac fibroblasts contribute directly to the pool of endothelial cells at the site of 
injury by adopting an endothelial phenotype.  Further, I show that endothelial cells derived 
from cardiac fibroblasts are incorporated into the vascular network and are capable of 
supporting blood flow. 
 
Chapter 3. To identify the signaling mechanisms that cause MEndoT to occur 
Previous studies have shown that p53 is upregulated in the heart after ischemic injury.  
More recently studies have also shown a role for p53 in conversion of cellular phenotypes in 
processes such as EMT.  To identify whether p53 plays a role in MEndoT we utilized an ex 
vivo serum starvation model system, which has been previously shown to increase p53 
levels in cells, to determine whether cardiac fibroblasts could be induced to undergo 
MEndoT.  After successfully demonstrating that labeled cardiac fibroblasts can adopt 
functional endothelial traits and upregulate endothelial-specific genes in the serum 
starvation model, we utilize p53-based gain and loss of function approaches to determine 
whether p53 plays a regulatory role in MEndoT.  We found that ex vivo pharmacological 
inhibition or deletion of p53 during serum starvation reduced MEndoT while increasing p53 
levels using a small molecule activator known as RITA increased MEndoT. 
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Chapter 4. To determine the functional role of MEndoT in cardiac repair 
After identifying that p53 regulates MEndoT in an ex vivo model system, I describe how we 
utilized p53-based gain and loss of function approaches to determine the physiological role 
of MEndoT in cardiac repair.  Using a p53 genetic deletion model, I show that in the 
absence of p53 in cardiac fibroblasts MEndoT is decreased, as is the cardiac vasculature at 
the site of injury.  I also demonstrate that lack of MEndoT is associated with reduced cardiac 
function and increased scarring.  Alternatively, increasing p53 levels in cardiac fibroblasts 
after cardiac injury through treatment with RITA led to an increase in MEndoT and an 
increase in cardiac vasculature at the site of injury.  This increase in vascularity was 
associated with improved heart function and reduced scar formation.  
 
Chapter 5. Conclusions and perspectives 
In this chapter I summarize the findings demonstrated in this dissertation.  I also describe 
some of the main limitations of the work and how they affect our current understanding of 
MEndoT.  In addition, I describe some of the outstanding questions that could be addressed 
in the future study of MEndoT as well as potential implications in the treatment of human 
cardiac disease.   
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Supplemental Material 
 
Table 1.1 Expression of Fibroblast Markers in Other Cell Types 
Fibroblast 
Marker 
Abbreviated 
Gene Name 
Other Cell Types 
Expressing References 
alpha-Smooth 
Muscle Actin αSMA 
Cardiomyocytes, 
Mesenchymal stem 
cells, Myoepithelial 
cells, Pericytes, 
Smooth muscle cells 
Potta et al. (2010), Chin et 
al. (2013), Katori et al. 
(2013), He et al. (1995), 
Kawasaki et al. (2008) 
CD40 n/a 
B cells, 
Carcinoma/Leukemia, 
Monocytes, Dendritic 
cells, Endothelial 
cells, Epithelial cells 
Clark et al. (1990), van 
Kooten et al. (2000) 
Collagen type I 
alpha 1 Col1a1 
Chondroblasts, 
Osteoblasts 
Perrier-Groult et al. 
(2013), Cleriques et al. 
(2012) 
Collagen type I 
alpha 2 Col1a2 Osteoblasts Duan et al. (2013) 
Fibroblast specific 
protein-1 
Fsp1 (or 
S100A4) 
Carcinoma, 
Macrophages, 
Myoepithelial cells, 
Smooth muscle cells 
Chao et al. (2012), 
Osterreicher et al. (2010), 
Katori et al. (2013), 
Sugimoto et al. (2006) 
Thymus cell 
antigen-1 Thy-1 (or CD90) 
Endothelial cells, 
Leukocytes 
Tuffin et al. (2008), 
Vermiere et al. (2011) 
Vimentin Vim 
Carcinoma, 
Endothelial cells, 
Myoepithelial cells, 
Pericytes, Smooth 
muscle cells  
Chao et al. (2012), 
Conway et al. (2013), 
Beha et al. (2012), 
Kokovay et al. (2006), 
Kacem et al. (1995) 
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CHAPTER 2 Cardiac fibroblasts undergo Mesenchymal-to-Endothelial Transition in 
response to acute cardiac injury 
 
Overview 
 
Objective:  After acute cardiac injury there is a close and coordinated relationship between 
fibroblasts and endothelial cells during their proliferative stage in the early fibrotic response.  
It has been previously demonstrated that after cardiac injury a subset of endothelial cells 
adopts a fibroblast fate through the process of Endothelial-to-Mesenchymal Transition 
(EndMT).  While cardiac fibroblasts are thought to be terminally differentiated cells, whether 
they can adopt an endothelial fate after injury is unknown.  We therefore sought to 
determine whether fibroblasts undergo the reverse process, Mesenchymal-to-Endothelial 
Transition (MEndoT), after acute ischemic injury. 
Methods and Results:  We utilized a fate mapping model to determine whether cardiac 
fibroblasts undergo MEndoT after ischemia reperfusion cardiac injury.  To do so, we utilized 
a tamoxifen inducible Cre recombinase driven by the fibroblast specific regulatory sequence 
of the alpha2 (Type 1) collagen gene (Col1a2-CreERT).  Tamoxifen treated Collagen1a2-
CreERT:R26RtdTomato reporter mice underwent ischemia reperfusion or sham injury, then 
cardiac sections were prepared 3, 7, and 14 days after injury and immunostained for 
endothelial-specific markers.  We observed that approximately 30% of labeled cardiac 
fibroblasts expressed endothelial markers after ischemia reperfusion injury but did not in 
sham injured animals.  We also utilized DiO perfusion and AcLDL uptake assays and found 
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that MEndoT cells are integrated into the vasculature and have functional traits of 
endothelial cells after injury. 
Conclusions: We demonstrate that after acute cardiac injury, a subset of cardiac fibroblasts 
adopt an endothelial fate through a process we have termed MEndoT.  We also 
demonstrate that MEndoT cells integrate with the vascular network and support blood flow 
at the site of injury. 
 
Introduction 
 
 Recent research has demonstrated that fibroblasts and endothelial cells possess 
cellular plasticity that is activated after cardiac injury.  Zeisberg and colleagues showed that 
a subset of resident endothelial cells adopt a fibroblast phenotype through the process 
known as Endothelial-to-Mesenchymal Transition (EndMT)1 in response to cardiac injury.  
From a therapeutic standpoint, the inhibition of EndMT led to reduced fibrosis and the 
negative cardiac remodeling associated with chronic pressure overload injury and suggests 
that manipulation of cellular plasticity could be a novel treatment for cardiac injury.   
 That led us to question whether in an ischemic model of cardiac injury if it was 
possible for fibroblasts to undergo the process of Mesenchymal-to-Endothelial Transition 
(MEndoT) and contribute to the pool of endothelial cells that restore the vasculature at the 
site of injury.  
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Materials and Methods 
Generation of transgenic mice 
All animal experiments were conducted in accordance with the University of North Carolina 
Institutional Animal Care and Use Committee (IACUC) guidelines.  Collagen1a2-
CreERT:R26RtdTomato mice were obtained by breeding Collagen1a2-CreERT mice2,3 with 
R26RtdTomato mice4.  Genetic labeling was achieved by injecting 8-10 week old Collagen1a2-
CreERT:R26RtdTomato  mice with1mg tamoxifen (Sigma) intraperitoneally daily for 10 days.  5 
days after cessation of tamoxifen the mice either underwent ischemia reperfusion or sham 
injury or cardiac fibroblasts were isolated. 
Cardiac injury model 
Mice were anesthetized with 3% isoflurane (Butler Schein), maintained at 2% isoflurane and 
intubated using a Harvard Rodent Volume-Cycled Ventilator.  Ischemia-reperfusion injury 
was induced by ligation of the left anterior descending (LAD) coronary artery for 30 minutes 
followed by reperfusion5.  Sham injury was performed using the same procedure but the 
ligature was not tightened to occlude blood flow.  At 3, 7, or 14 days the injured animals 
were anesthetized with pentobarbital (45mg/kg) and the left ventricle perfused with 5ml PBS 
(Gibco) followed by 2ml 4% paraformaldehyde (Electron Microscopy Sciences).  For DiO 
staining of cardiac vasculature, DiO was prepared as described6 and 2 ml of 120µg/ml DiO 
was perfused prior to PFA perfusion.  For AcLDL staining, 1µg Alexa488 conjugated AcLDL 
was injected via jugular vein catheter and the heart harvested as described 4 hours later.  
After perfusion, the heart was isolated and fixed for 1 hour in 4% paraformaldehyde at 4oC.  
Then the heart was fixed for an addition 4 hours in new 4% paraformaldehyde solution at 
4oC.  Hearts were then sucrosed embedded overnight at 4oC in a 30% sucrose (MP 
Biochemicals) solution and frozen in OCT (Tissue-Tek). 
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Immunofluorescent staining , confocal imaging, and quantitation 
Frozen sections (7µm thick) were prepared from hearts isolated 3, 7, or 14 days after 
ischemia reperfusion or sham injury of tamoxifen treated Col1a2CreERT:R26RtdTomato mice.  
Frozen sections were also prepared from uninjured tamoxifen treated 
Col1a2CreERT:R26RtdTomato mice.  Prepared sections were permeabilized for 10 minutes in 
acetone at -20oC, washed with PBS, and blocked with 10% normal goat serum with 1% 
BSA.  Staining was subsequently carried out using a primary antibody to VECAD, eNOS, 
Claudin 5, Occludin, alpha-SMA, or CD68 (Abcam) and an associated fluorescently 
conjugated secondary antibody (Millipore). Table 2.1 outlines specific information for each 
antibody used.   WGA staining of frozen sections from ischemia-reperfusion injured mice 
was performed as described7.  DAPI stain was incorporated to visualize nuclei.  Imaging of 5 
non-overlapping areas of the injury border zone or areas distal to the border zone was 
performed for sections from each animal using the Lieca SP2 AOBS Upright Laser Scanning 
Microscope (Leica).  Quantitation of colocalization was performed using ImageJ software 
(NIH).  To determine the percentage of cells undergoing MEndoT, the number of tdTomato 
labeled cells colocalized with an endothelial marker were divided by the total number of 
tdTomato labeled cells.  For determination of luminal surface area occupied by tdTomato 
cells the Manders coefficient of colocalization was determined using the JACoP8 plugin for 
ImageJ. 
Fibroblast isolation and culture 
Cardiac fibroblasts were isolated from uninjured tamoxifen treated Col1a2-
CreERT:R26RtdTomato mice.  At 8-10 weeks of age, hearts were isolated from euthanized 
mice.  After washing 3 times with 1X HBSS (Gibco) the hearts were minced with a razor into 
approximately 1mm2 pieces and digested using 5ml of a 0.1% Trypsin solution (Gibco) with 
50U/ml Collagenase II (Worthington).  5 sequential digestions were performed and the 
supernatant filtered through a 40µm strainer and the trypsin neutralized with Fetal Bovine 
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Serum (FBS).  Cells were cultured for 1 hour at 37oC in IMDM, 1X Penicillin/Streptomycin, 
10% FBS (Gibco).  After 1 hour the medium was changed to F12K, 1X 
Penicillin/Streptomycin, 10% FBS (Gibco), 10ng/ml Leukemia Inhibitory Factor (LIF) 
(Millipore), and 10ng/ml bFGF (Millipore).  Cells were grown at 37oC, 5% CO2 for 7-10 days 
until they became confluent. 
Flow cytometry 
Analytical flow cytometry was performed for cell surface markers using fluorophore 
conjugated antibodies to Thy1, CD31, VECAD, and c-Kit (eBioscience).  Table 2.1 outlines 
specific information for each antibody.  Cultured cardiac fibroblasts were dissociated using 
Accutase (Innovative Cell Technologies, Inc.) and immunostained in 0.1% BSA in PBS.  
Labeling was conducted at 1x106 cells/ml for 20-30 minutes at 4oC, followed by 2 washes 
with 0.1% BSA in PBS, and subsequent analysis on a Beckman-Coulter CyAn ADP 
instrument with Summit software (Dako). 
 
Results 
 
To determine whether cardiac fibroblasts adopt an endothelial fate after cardiac 
injury, we utilized a genetic fate mapping strategy based on the use of Cre/Lox technology.  
To enable our strategy we crossed mice harboring a tamoxifen inducible Cre recombinase 
driven by the fibroblast specific regulatory sequence of the alpha2 (Type 1) collagen gene 
(Col1a2-CreERT) with the lineage reporter strain R26RtdTomato.  When the mice were bred 
together we obtained Col1a2-CreERT:R26RtdTomato mice.  When these mice were injected 
with tamoxifen, the Cre recombinase became activated and led to the indelible labeling of 
cells expressing Col1a2 and their progeny.   
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To determine the efficiency of tdTomato fluorescent labeling in our fate mapping 
model, we injected Col1a2-CreERT:R26RtdTomato mice with tamoxifen for 10 days starting at 
8-10 weeks of age.  Cardiac fibroblasts were harvested by differential attachment9 5 days 
after the cessation of tamoxifen.  Using flow cytometry, we observed that 70% of cardiac 
fibroblasts isolated were tdTomato positive (Figure 2.1a).  While there are no completely 
specific markers for fibroblasts, Thy1 is known to be robustly expressed in cardiac 
fibroblasts10.  We observed that 71.2% of Thy1 positive cells also expressed tdTomato 
(Figure 2.1b).   
We also sought to determine whether tdTomato labeling was specific to fibroblasts.  
To do so, we isolated cardiac fibroblasts from tamoxifen treated uninjured Col1a2-
CreERT:R26RtdTomato mice and analyzed them for the expression of the endothelial markers 
VECAD and CD31.   We observed that 99.9±0.06% and 99.8±0.02% (mean±S.E.M.) of 
labeled cells did not express VECAD and CD31, respectively (Figure 2.2).  To further 
determine the specificity of labeling, we immunostained cardiac sections prepared from 
tamoxifen treated uninjured Col1a2-CreERT:R26RtdTomato mice.  We observed that 99.4% 
and 100% of tdTomato labeled cells did not express αSMA and the macrophage marker 
CD68, respectively (Figure 2.3).  We have previously shown that in this reporter mouse 
cardiomyocytes are not labeled11.  We also assayed whether tdTomato labeled cells 
expressed c-Kit and found that 99.98±0.02% (mean±S.E.M.) were negative (Figure 2.4).  
Taken together, our results demonstrate that labeling of cardiac fibroblasts in our system is 
both specific and efficient. 
Prior to determining whether cardiac injury could induce fibroblasts to adopt an 
endothelial phenotype we sought to confirm that Cre recombinase is not activated during 
cardiac injury.  To do so we treated Col1a2-CreERT:R26RtdTomato mice with corn oil, the 
vehicle used during tamoxifen injections, and subjected the mice to ischemia reperfusion 
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cardiac injury.  3 days after injury the hearts were harvested, sectioned, and immunostained 
with Alexa488 conjugated wheat germ agglutinin (WGA) to label plasma membranes as a 
counterstain.  We observed that of the approximately 38,000 cells counted, only 28 were 
tdTomato labeled (0.07%) (Figure 2.5).   
After validating our fate mapping model, we sought to determine whether cardiac 
injury would induce labeled cardiac fibroblasts to adopt an endothelial fate.  We subjected 
tamoxifen treated Col1a2-CreERT:R26RtdTomato mice to either sham or ischemia reperfusion 
injury 5 days after the cessation of tamoxifen.  Hearts were harvested 3 days after injury and 
immunostained for the endothelial specific markers VECAD, eNOS, Claudin 5 and Occludin.  
We observed that endothelial markers were expressed in labeled fibroblasts of ischemia 
reperfusion injured hearts (Figure 2.6b) but not in sham injured hearts (Figure 2.6a).  We 
quantitated the percentage of labeled fibroblasts cells expressing VECAD, eNOS, Claudin 5, 
and Occludin and determined that 35±3%, 24.4±4%, 44±4%, 35±3% (mean±S.E.M.) of 
tdTomato labeled cells expressed each marker, respectively (Figure 2.6c).  Alternatively, in 
sham injured animals VECAD, eNOS, Claudin 5, and Occludin were expressed in 0.3%, 1%, 
2%, and 2% of labeled fibroblasts, respectively (Figure 2.6c).  We also observed that the 
number of endothelial marker expressing cardiac fibroblasts was relatively higher at the 
injury border zone and was reduced by approximately 60% at sites distal to the injury 
(Figure 2.6c).  We next sought to determine the temporal expression of the endothelial 
marker VECAD in labeled fibroblasts.  We observed that the percentage of labeled 
fibroblasts undergoing MEndoT was similar at 3, 7, and 14 days after injury (Figure 2.6d). 
  After determining that cardiac fibroblasts express endothelial markers, we assayed 
whether MEndoT cells are incorporated into the vasculature at the site of injury.  To do so, 
we perfused sham and ischemia reperfusion injured Col1a2-CreERT:R26RtdTomato mice with 
the lipophilic dye DiO.  When perfused, DiO will incorporate into the plasma membranes of 
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cells lining the lumen of blood vessels.  The dye then migrates within the plasma membrane 
of the exposed cells but will not move from cell to cell6.  At 3, 7, and 14 days after injury, we 
perfused the vasculature with DiO and observed that in sham injured hearts <1% of the 
luminal surface area was occupied by tdTomato labeled cardiac fibroblasts (Figure 2.7e,j).  
However, after ischemia reperfusion injury, at 3, 7, and 14 days after injury 19±3%, 34±6%, 
and 36±6% (mean±S.E.M.) of luminal surface area was derived from labeled cardiac 
fibroblasts, respectively (Figure 2.7f-j). 
In addition to DiO perfusion, we also tested whether labeled cardiac fibroblasts could 
take up AcLDL, which is characteristic of endothelial cells12.  Three days after injury of 
tamoxifen treated Col1a2-CreERT:R26RtdTomato mice, Alexa488 conjugated AcLDL was 
injected via jugular catheter.  After 4 hours the hearts were harvested and sectioned.  We 
observed that in sham injured hearts, labeled fibroblasts did not take up AcLDL (Figure 
2.8a) but after injury they did (Figure 2.8b).   
As previously described, after cardiac injury fibroblasts can adopt a myofibroblast 
phenotype.  We sought to determine whether the sub-population of fibroblasts undergoing 
MEndoT is separate from those adopting the myofibroblast phenotype.  To answer this 
question we immunostained for αSMA, which is characteristic of myofibroblasts, and 
VECAD in cardiac sections prepared 3 days after ischemia reperfusion injury in Col1a2-
CreERT:R26RtdTomato mice.  We observed that αSMA expressing fibroblasts did not express 
VECAD (Figure 2.9), suggesting that the two populations are distinct.   
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Discussion 
 
 To the best of our knowledge, the process of MEndoT has not been previously 
described either during development or in any organ system after injury.  Our finding is also 
novel because cardiac fibroblasts are thought to be terminally differentiated cells that are 
unable to adopt alternative phenotypes13,14.  Recent work has focused on reprogramming 
cardiac fibroblasts to adopt other fates using exogenous transcription factors15,16.  Our 
findings demonstrate that cardiac fibroblasts have a degree of native plasticity and that a 
subset of fibroblasts adopts an endothelial phenotype after injury in the absence of added 
exogenous factors.   
 Our findings also show that in addition to regulating angiogenesis after injury, 
fibroblasts can provide a robust source of endothelial cells at the site of ischemic, directly 
contribute to the revascularization of the ischemic region and potentially enhance cardiac 
repair.    
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Figure 2.1 Labeling of cardiac fibroblasts in Col1a2-CreERT:R26RtdTomato mice is 
efficient. 
 
(a-b) Cardiac fibroblasts were isolated from uninjured 8-10 week old Col1a2-
CreERT:R26RtdTomato mice after 10 days of intraperitoneal tamoxifen injection. (a) Harvested 
cardiac fibroblasts were isolated by differential attachment and flow cytometry was utilized to 
determine the percentage of tdTomato labeled cells. (b) The percentage Thy1 positive cells 
expressing the tdTomato label was determined by flow cytometry. 
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Figure 2.2 Col1a2-CreERT:R26RtdTomato labeled cardiac fibroblasts do not express 
endothelial specific markers. 
 
(a-b) Cardiac fibroblasts were isolated from uninjured 8-10 week old tamoxifen injected 
Col1a2-CreERT:R26RtdTomato mice and analyzed by flow cytometry for the expression of (a) 
VECAD or (b) CD31.   
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Figure 2.3  Labeling of cardiac fibroblasts in Col1a2-CreERT:R26RtdTomato mice is 
specific. 
  
(a-b) Frozen heart sections were prepared from uninjured 8-10 week old tamoxifen injected 
Col1a2-CreERT:R26RtdTomato mice and immunostained for (a) alpha Smooth Muscle Actin or 
(b) the macrophage marker CD68. 
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Figure 2.4 Col1a2-CreERT:R26RtdTomato labeled cardiac fibroblasts are not positive for 
the stem cell marker c-Kit. 
 
(a) Cardiac fibroblasts were isolated from uninjured 8-10 week old tamoxifen injected 
Col1a2-CreERT:R26RtdTomato mice and analyzed by flow cytometry for the expression of c-
Kit.   
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Figure 2.5 Cre recombinase is not activated by ischemia reperfusion cardiac injury. 
 
(a-c) Frozen heart sections were prepared from ischemia reperfusion injured 8-10 week old 
tamoxifen injected Col1a2-CreERT:R26RtdTomato mice three days after injury.  Sections were 
stained with (a) Alexa488 conjugated wheat germ agglutinin (WGA) to stain plasma 
membranes.  (b-c) Visualization of (b) tdTomato labeled cells and colocalization in (c) 
merged image show rare labeled cells (28 labeled cells out of 38,000 counted (0.07%), n=3 
animals).  
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Figure 2.6 Cardiac fibroblasts express endothelial markers after acute cardiac injury. 
 
(a-b) Tamoxifen treated 8-10 week old Col1a2-CreERT:R26RtdTomato mice were subjected to 
(a) sham or (b) ischemia reperfusion injury.  Hearts were harvested 3 days after injury, 
sectioned and immunostained for VECAD, eNOS, Claudin 5, and Occludin.  Colocalization 
is indicated by arrowheads (n=3 animals, scale bar = 10µm). (c) Percentage of cardiac 
fibroblasts expressing endothelial markers at the border zone and distal to the site of injury 
(*p<0.005 compared to sham except for eNOS and Claudin 5 which are p<0.05; †p<0.005 
compared to injury border zone except for eNOS and Claudin 5 which are p<0.05; n=3 
animals). (d) Temporal expression of VECAD by cardiac fibroblasts at the injury border zone 
(*p<0.005 compared to sham, n=3 animals per time point). 
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Figure 2.7 Cardiac fibroblasts occupy a luminal position after injury. 
 
(a-e) Tamoxifen treated 8-10 week old Col1a2-CreERT:R26RtdTomato were subjected to (a) 
sham or (b-e) ischemia reperfusion injury and hearts were DiO perfused and harvested 3 
days after injury.  (b) Longitudinal and (c-e) transverse sections of blood vessels in which 
labeled cardiac fibroblasts are DiO stained (arrowheads indicate fluorophore colocalization, 
open arrowhead indicates a DiO labeled endothelial cell; scale bar in (b) = 10µm, scale bar 
in (e) = 5µm; n=3 animals).  (f) Quantitation of the percentage of the luminal endothelial 
surface derived from labeled cardiac fibroblasts at 3, 7, and 14 days after injury (*p<0.005 
compared to sham, †p<0.05 compared to Day 3, n=3 animals at each time point). 
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Figure 2.8 Cardiac fibroblasts take up Acetylated LDL after acute cardiac injury. 
 
(a-b) Tamoxifen treated 8-10 week old Col1a2-CreERT:R26RtdTomato mice were subjected to 
(a) sham or (b) ischemia reperfusion injury, 3 days later Alexa488 conjugated AcLDL was 
injected, and after 4 hours the heart was harvested (open arrowheads indicate cells taking 
up AcLDL, arrowheads indicate colocalized fluorophores, scale bar = 5µm, n=3 animals).   
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Figure 2.9 Cardiac fibroblasts that undergo MEndoT do not express alpha Smooth 
Muscle Actin. 
 
(a-d) Tamoxifen treated 8-10 week old Col1a2-CreERT:R26RtdTomato mice were subjected to 
ischemia reperfusion injury and hearts were isolated 3 days later.  Hearts sections show (a) 
labeled cardiac fibroblasts, (b) VECAD expressing cells, (c) alpha Smooth Muscle Actin 
expressing cells, and (d) colocalization of labeled fibroblasts and alpha Smooth Muscle 
Actin are indicated by arrowheads and colocalization of labeled fibroblasts and VECAD 
indicated by an arrow (n=3 animals). (e) Percentage of labeled cardiac fibroblasts 
expressing alpha Smooth Muscle Actin and VECAD (*p<0.005). 
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Supplemental Material 
Table 2.1 Antibody Information 
Application Antibody Vendor Catalog Number 
Immunostaining 
VECAD Abcam ab33168 
eNOS Abcam ab66127 
Claudin 5 Abcam ab53765 
Occludin Abcam ab31721 
αSMA Abcam ab5694 
CD68 Abcam ab125212 
Flow cytometry 
Thy1 eBioscience 17-0902-81 
VECAD eBioscience 17-1441-80 
CD31 eBioscience 17-0311 
c-Kit BD Bioscience 561074 
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CHAPTER 3 p53 Mediates MEndoT ex vivo 
 
Overview 
 
Objective:  As a result of ischemia reperfusion injury, cells downstream of the occlusion are 
exposed to multiple forms of cellular stress such as hypoxia, nutrient deprivation and ROS.  
The MAPK pathway and p53 have been previously described as mediators of cellular stress 
in response to each of the aforementioned stressors.  As p53 has been demonstrated to 
play a role in cell phenotype conversion, in this study we sought to determine whether p53 
plays a role in the regulation of MEndoT. 
Methods and Results:  We demonstrate that p53 is upregulated in cardiac fibroblasts at the 
injury border zone after ischemia reperfusion injury.  We also demonstrate that cardiac 
fibroblasts subjected to serum starvation ex vivo upregulate p53.  Using multiple functional 
assays in our ex vivo model, we show that serum starvation can induce labeled cardiac 
fibroblasts to adopt endothelial traits in a p53 dependent manner.  Inhibition of p53 signaling 
by pharmacological or genetic means disrupted MEndoT.  Using a small molecule, RITA, to 
activate p53 we also observed that MEndoT in our ex vivo model could be increased. 
Conclusions: Taken together, our results demonstrate that MEndoT following cellular 
stress occurs in a p53 dependent manner. 
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Introduction 
 
Following ischemic cardiac injury, cells downstream of the coronary occlusion are 
exposed to stress caused by the disruption of blood flow.  The two main forms of cellular 
stress in ischemic regions are hypoxia and nutrient deprivation as the flow of oxygen and 
nutrients normally delivered by the blood are abruptly reduced1.  Both forms of stress 
contribute to the death of dependent myocardium and trigger the wound healing response 
described earlier.  In the event that blood flow is restored, as would be the case during 
medical intervention, reperfusion injury can also occur.  In this case reactive oxygen species 
(ROS) are generated as a byproduct of altered post-ischemic cellular metabolism.  The ROS 
reduce the integrity of the surrounding cellular membranes and can lead to mitochondria 
mediated apoptosis2,3.    
The three aforementioned forms of stress have been previously demonstrated to 
elicit the cellular stress response through the Mitogen Activated Protein Kinase (MAPK) 
signaling pathway in the ischemia reperfusion injured heart 4,5.  As shown in Figure 3.1, one 
of the key effectors of the MAPK pathway is p53.  p53 is evolutionarily conserved6,7 and has 
been dubbed the “guardian of the genome”8 for its roles in regulating cell cycle progression 
and the DNA damage response9.  If the genome becomes compromised after DNA damage 
p53 holds the cell cycle in check until the DNA can be repaired.  If the DNA cannot be 
repaired, p53 is a key initiator of the apoptotic pathway.   
In recent studies, p53 has also been found to play conflicting roles in cell 
differentiation and reprogramming.  Kawamura and colleagues determined that reduction in 
p53 led to improvements in the efficiency of generating iPSCs10.  Alternatively, Molchadsky 
and colleagues discovered that context dependent cellular differentiation of mesenchymal 
progenitor cells was based on the regulation of p53.  In their studies, Molchadsky and 
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colleagues determined that p53 inhibits differentiation into osteogenic, adipogenic, and 
myofibroblast phenotypes while p53 positively regulates the differentiation into skeletal 
muscle cells11. 
In two other studies Kim et al and Chang et al reported that p53 suppresses 
epithelial-to-mesenchymal transition (EMT) 12,13.  Additionally, Chang and colleagues 
demonstrated that when miR-200c, which is positively regulated by p53 activity, was 
restored after p53 deletion the cells reverted to a mesenchymal phenotype through the 
process of mesenchymal-to-epithelial transition (MET).   
Extensive study of p53 has elucidated the protein structure and how it interacts with 
DNA (Figure 3.2)14.  These findings have allowed researchers to develop pharmacological 
tools to manipulate p53 activity.  As an example, an inhibitor of p53 activity called Pifithrin-α 
has been developed and can effectively block the DNA binding domain of p5315,16.  To some 
extent, reduction of p53 mediated apoptosis using Pifithrin-α has been studied as a 
treatment for cardiomyocyte preservation after myocardial infarction17,18,19,20.  Unfortunately, 
to date the studies have shown limited ability to improve overall wound healing.   
Conversely, researchers have also discovered a means for positively regulating p53 
activity based on the manipulation of the interaction between the p53 trans-activation 
domain (TAD) and MDM2, an E3 poly-ubiquitin ligase that adds a series of ubiquitins and 
thereby targets p53 for proteosomal degradation.  In the event that the interaction between 
p53 and MDM2 is blocked, as is the case in the presence of the small molecule Reactivator 
of p53 Induced Tumor cell Apoptosis (RITA), p53 levels within the cell increase because 
proteosomal degradation is inhibited, which ultimately leads to cell cycle arrest or apoptosis.  
Applications of high doses of RITA have been studied as an approach to inducing apoptosis 
in cancerous cells21,22,23,24. 
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Given that the activity of p53 was able to cause MET, we hypothesized that injury 
induced activation of p53 may similarly induce mesenchymal-to-endothelial transition 
(MEndoT).  Utilizing our genetically labeled fibroblasts we developed an ex vivo model 
system that mimics post-ischemic injury induced cellular stress and recapitulates the 
MEndoT seen in vivo.  Further, by manipulating p53 activity both positively and negatively, 
using RITA and Pifithrin-α respectively, we demonstrate that MEndoT is mediated by p53 
activity.  
 
Materials and Methods 
 
Immunofluorescent staining of heart sections and relative p53 protein level 
determination 
Frozen sections (7µm thick) were prepared from hearts isolated 3 days after injury from 
ischemia reperfusion or sham injured tamoxifen treated Col1a2-CreERT:R26RtdTomato mice.  
Sections were permeabilized for 10 minutes in acetone at -20oC, washed with PBS, and 
blocked with 10% normal goat serum with 1% BSA.  Staining was subsequently carried out 
using a primary antibody to p53 (Abcam) and an associated fluorescently conjugated 
secondary antibody (Millipore).  DAPI stain was incorporated to visualize nuclei.  Imaging 
was performed using the Lieca SP2 AOBS Upright Laser Scanning Microscope (Leica).  p53 
localization in labeled cardiac fibroblasts was determined using the Manders coefficient as 
determined by the JACoP plugin of Image J software (NIH). 
Fibroblast isolation and culture 
Cardiac fibroblasts were isolated from uninjured tamoxifen treated Col1a2-
CreERT:R26RtdTomato, Col1a2-CreERT:p53fl/fl 25 or C57B/6 mice.  At 8 weeks of age, hearts 
were isolated from euthanized mice.  After washing 3 times with 1X HBSS (Gibco) the 
hearts were minced with a razor to approximately 1mm2 pieces and digested using 5ml of a 
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0.1% Trypsin solution (Gibco) with 50U/ml Collagenase II (Worthington).  5 sequential 
digestions were performed and the supernatant filtered through a 40µm strainer and trypsin 
neutralized with Fetal Bovine Serum (FBS).  Cells were cultured for 1 hour at 37oC in IMDM, 
1X Penicillin/Streptomycin, 10% FBS (Gibco).  After 1 hour the medium was changed to 
F12K, 1X Penicillin/Streptomycin, 10% FBS (Gibco), 10ng/ml Leukemia Inhibitory Factor 
(LIF) (Millipore), and 10ng/ml bFGF (Millipore).  Cells were grown at 37oC, 5% CO2 for 7-10 
days until they became confluent. 
Western blotting 
Protein was isolated from cardiac fibroblasts cultured for 48 hours at 37oC, 5% CO2 in the 
presence or absence of FBS (IMDM, 1X Penicillin/Streptomycin, ±10% FBS).  Isolated 
protein was concentration normalized, prepared with an SDS loading buffer, and run on a 
12X Mini-PROTEAN TGX gel (BioRad) at 300V for 25 minutes.  The protein was transferred 
to a nitrocellulose membrane using the Trans-Blot Turbo System (BioRad).  The membrane 
was blocked using TBST+3% cold fish gelatin and probed using antibodies to p53 (Abcam) 
and alpha-Tubulin (Sigma).  After washing, the bound primary antibodies were labeled with 
fluorescently conjugated secondary antibodies (LI-COR Biosciences).  After washing with 
TBST the probed membranes were visualized on an Odyssey scanner (LI-COR 
Biosciences).  Densitometry analysis was performed using ImageJ software (NIH). 
Matrigel assay 
Labeled fibroblasts (Col1a2-CreERT:R26RtdTomato), p53 deleted fibroblasts (Col1a2-
CreERT:p53fl/fl), or C57B/6 fibroblasts were seeded on a Matrigel coated well at a density of 
6X104 cells per cm2 and cultured for 24 hours at 37oC, 5% CO2.  Cells were grown in the 
presence or absence of FBS (IMDM, 1X Penicillin/Streptomycin, ±10% FBS).  During 
pharmacological treatment studies, medium was supplemented with 100µM Pifithrin-α or 
0.1µM RITA.  The length of endothelial tube-like structures was quantitated using ImageJ 
software (NIH). 
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AcLDL uptake 
Fibroblasts cultured for 48 hours in the presence or absence of serum (IMDM, 1X 
Penicillin/Streptomycin, ±10% FBS) were incubated with Alexa488 conjugated acetylated 
low density lipoprotein (AcLDL) (Invitrogen) for 4 hours at 37oC, 5% CO2.  Uptake was 
visualized using the Lieca SP2 AOBS Upright Laser Scanning Microscope (Leica) either in 
the XY or XZ plane.   
qRT-PCR 
C57B/6 fibroblasts, or fibroblasts with or without p53 deleted (Col1a2-CreERT:p53fl/fl or 
Col1a2-CreERT:p53+/+) were grown in the presence or absence of FBS (IMDM, 1X 
Penicillin/Streptomycin, ±10% FBS) for 48 hours at 37oC, 5% CO2.  During pharmacological 
treatment studies, medium was supplemented with 100µM Pifithrin-α or 0.1µM RITA.  After 
treatment, RNA was isolated and reverse transcription performed with the SV Total RNA 
Isolation Kit and Reverse Transcription System (Promega), respectively.  qPCR was 
performed using the SensiMix SYBR and Fluorescein Kit (Quantace) and an iQ5 thermal 
cycler (BioRad).  qPCR primer sequences are listed in Supplemental Material 
Table 3.1. 
 
Results 
 
To confirm that p53 was upregulated in cardiac fibroblasts at the injury border zone, 
we performed immunofluorescent staining for p53 in frozen heart sections prepared from 
Col1a2-CreERT:R26RtdTomato mice 3 days after either ischemia reperfusion or sham injury.  
We observed that p53 levels were increased 6±0.7 fold (mean±S.E.M, p<0.005) in labeled 
cardiac fibroblasts after IR as compared to sham (Figure 3.3).   
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To further study the potential role of p53 in MEndoT, we developed an ex vivo model 
system.  Others have shown that p53 levels are increased in cells exposed to serum 
starvation26,27,28,29 so we sought to determine whether p53 was similarly upregulated in 
cardiac fibroblasts subjected to serum starvation.  To test this, we isolated cardiac 
fibroblasts and subjected them to serum starvation for 48 hours and compared p53 protein 
levels between starved and unstarved cells using Western blotting.  We found that in the ex 
vivo serum starvation model system p53 levels were increased by 2.3±0.2 fold 
(mean±S.E.M, p<0.005) (Figure 3.4).   
After demonstrating that cardiac fibroblasts subjected to serum starvation ex vivo 
upregulated p53 similarly to cardiac fibroblasts following ischemic injury we next determined 
whether fibroblasts subjected to serum starvation adopted endothelial cell characteristics. 
The first assay utilized Matrigel, a well characterized basement membrane substrate 
that facilitates tube formation of endothelial cells30.  If cardiac fibroblasts adopt endothelial 
traits after serum starvation then we hypothesize that they will form endothelial-like 
structures when cultured on Matrigel in the absence of serum. After sorting labeled cardiac 
fibroblasts to >95% purity, we seeded the cells on Matrigel and cultured them in the 
presence or absence of serum for 24 hours.  We found that when cultured in medium 
containing serum, labeled fibroblasts did not form tubes (Figure 3.5a).  However, when 
grown in the absence of serum fibroblasts did form capillary tube-like structures.  The 
endothelial-like structures also expressed the endothelium-specific gene VECAD (Figure 
3.5b).   
The second functional assay for endothelial cell traits relies on the ability of 
endothelial cells to internalize acetylated low density lipoprotein (AcLDL).  This action is 
facilitated by the LDL receptor protein expressed and localized to the surface of endothelial 
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cells.  Uptake of AcLDL has been a hallmark of endothelial cells since its discovery almost 
30 years ago31.  Using our serum starvation model system we found that fibroblasts grown 
in serum replete conditions do not take up AcLDL (Figure 3.5c).  However, after 48 hours of 
serum starvation they do (Figure 3.5d-e).  To further demonstrate internalization of AcLDL in 
MEndoT cells, we utilized confocal imaging in the XZ plane and observed penetration of the 
fluorophore conjugated AcLDL into the cell (Figure 3.5e).   
Together, these finding demonstrate that serum starvation of cardiac fibroblasts 
recapitulates the increased p53 expression and the MEndoT that takes place after cardiac 
injury.  To further explore whether p53 plays a role in MEndoT in our ex vivo model system 
we utilized gain and loss of function approaches using existing genetic and pharmacological 
tools. 
The loss of function approach was performed using both a pharmacological inhibitor 
of p53 activity, Pifithrin-α, and a p53fl/fl mouse for genetic deletion.  As described previously, 
Pifithrin-α inhibits p53 activity by blocking its DNA binding region and reducing its function as 
a transcription factor.  To confirm and corroborate our findings with Pifithrin- α we utilized a 
genetic deletion model in which our tamoxifen inducible fibroblast specific Cre (Col1a2-
CreERT) was crossed to p53fl/fl mice.  After breeding the mice to attain Col1a2-
CreERT:p53fl/fl mice, we were able to use tamoxifen treatment to specifically delete p53 in 
fibroblasts in a temporally controlled fashion.  Using our ex vivo serum starvation on Matrigel 
model, we found that endothelial-like structure formation was significantly reduced in 
Pifithrin-α treated C57B/6 cardiac fibroblasts and p53 deleted cardiac fibroblasts 
(Col1a2CreERT:p53fl/fl (CKO)) as compared to PBS treated controls and those with intact 
p53, respectively (Figure 3.6b-d,f).   
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For gain of function studies we utilized a small molecule activator of p53 known as 
RITA.  As previously described, RITA has been studied as a method to increase p53 levels 
in cells by blocking MDM2 mediated poly-ubiquitination and subsequent proteosomal 
degradation of p53, therefore leading to increased p53 levels.  We found that when treated 
with 0.1µM RITA during serum starvation, the length of endothelial-like tube formation was 
significantly increased relative to PBS treated controls (Figure 3.6b,e-f). 
To confirm our findings from the Matrigel assay, we determined the relative 
expression of endothelial genes in serum starved cardiac fibroblasts using qRT-PCR (Figure 
3.6g).  After culturing cardiac fibroblasts isolated from uninjured C57B/6 mice in the 
presence or absence of serum for 48 hours, we found that endothelial gene expression was 
increased in serum starved cells.  We further assayed whether loss of p53 function, either by 
culturing the fibroblasts in medium containing 0% serum supplemented with 100µM Pifithrin-
α or through genetic deletion of p53 prior to serum starvation, would reduce endothelial 
gene expression.  We observed by qRT-PCR that pharmacological inhibition or genetic 
deletion of p53 significantly reduced expression of endothelial genes after serum starvation.  
We also determined whether culturing the cardiac fibroblasts with 0.1µM RITA could 
enhance endothelial gene expression during serum starvation.  We observed that 
endothelial gene expression was approximately doubled with RITA treatment during serum 
starvation as compared to PBS treated controls. 
 
Discussion 
 
 Taken together, our findings demonstrate that in an ex vivo model of cellular stress, 
cardiac fibroblasts upregulate p53 expression and adopt an endothelial phenotype.  Further, 
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applying gain and loss of function approaches to our ex vivo model system we have 
demonstrated that MEndoT occurs in a p53 dependent manner.   
 Next we wanted to determine the physiological significance of MEndoT in vivo.  It is 
well established that accelerated or augmented neovascularization of the wound region 
ameliorates post-ischemic injury induced decline in cardiac function.  We hypothesized that 
increasing MEndoT by increasing p53 levels after injury may similarly improve wound 
healing and cardiac function.  
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Figure 3.1 MAPK Signaling in Response to Cellular Stress 
 
The response to 3 key forms of cellular stress that occur after ischemia reperfusion cardiac 
injury are mediated by the MAPK signaling pathway.  
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Figure 3.2 p53 structure 
 
During DNA binding p53 acts as a tetramer (subunits shown in brown, green, pink and blue).  
The locations of the trans-activation domain (TAD) and DNA binding domain are indicated 
by white lines. DNA is shown as an orange and gray helix. 
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Figure 3.3 Cardiac fibroblasts upregulate p53 after cardiac injury. 
 
(a-b) Col1a2-CreERT:R26RtdTomato mice underwent either (a) sham or (b) ischemia 
reperfusion injury.  Hearts were harvested 3 days after injury and immunostained for p53 
(Arrowheads indicate labeled fibroblasts expressing p53, n=3, scale bar = 10µm).  (c) Fold 
change of p53 expression in labeled cardiac fibroblasts at the injury border zone (n=3, 
*p<0.005).  
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Figure 3.4 Serum starvation leads to upregulation of p53 in cardiac fibroblasts. 
 
(a-b) Cardiac fibroblasts isolated from uninjured C57B/6 mice were grown in the presence or 
absence of serum for 48 hours, protein was isolated, and Western blot analysis was 
performed.  (a) Western blot demonstrating p53 levels in cells cultured in 10% or 0% serum 
with alpha Tubulin as a loading control.  (b) Densitometry analysis quantitating the fold 
change increase of p53 in fibroblasts cultured in 0% serum as opposed to 10% serum (n=4, 
*p<0.005).  
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Figure 3.5 Cardiac fibroblasts adopt an endothelial phenotype in response to serum 
starvation. 
 
(a-b) Cardiac fibroblasts isolated from uninjured Col1a2-CreERT:R26RtdTomato mice were 
cultured on Matrigel for 24 hours in the (a) presence or (b) absence of serum (arrowheads 
indicate colocalization of tdTomato label and immunostained VECAD in endothelium-like 
structures, n=4).  (c-d) Col1a2-CreERT:R26RtdTomato cardiac fibroblasts were cultured in the 
(c) presence or (d) absence of serum for 48 hours and imaged 4 hours after incubation with 
Alexa488 conjugated AcLDL. Right panel of (d) is in the XZ plane to shown internalization 
(arrowheads indicate colocalization of fluorophores, n=4).   
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Figure 3.6 p53 mediates MEndoT in an ex vivo model system of cellular stress. 
 
(a-f) Endothelium-like structure formation of cardiac fibroblasts cultured on Matrigel for 24 
hours in medium containing (a) 10% serum, (b-e) 0% serum.  Fibroblasts were cultured with 
(c) 100µM Pifithrin, (e) 0.1µM RITA, or (d) after genetic deletion of p53 (n=3).  (f) Total 
length of endothelium-like structures from (a-e) quantitated using ImageJ software 
(**p<0.005 compared to cells cultured in 10% serum, †p<0.005 compared to cells cultured in 
0% serum plus PBS, *p<0.05 compared to cells cultured in 0% serum).  (g) qPCR for 
expression of endothelial genes in cardiac fibroblasts treated as described (*p<0.005 
compared to cells cultured in 10% serum, †p<0.05 compared to cells cultured in 0% serum 
plus PBS, n=8). 
 
 
53 
 
Supplemental Material 
Table 3.1 qPCR Primer Information 
  
Primer Sequence (5’-3’) 
Gene 
Name 
mRNA Accession 
Number Forward  Reverse 
VECAD NM_009868.4 tgcccaccatcgccaaaaga  tttcccacatagtggggcag 
Flt-1 NM_010228.3 ggtgtctgcttctcacagga  agagtctggcctgcttgcat 
Flk-1 NM_010612.2 tcagctatgccggcatggtc  gcggggggctcagaatcaca 
Claudin 5 NM_013805.4 gccgtcgggtgagcattcag gccaggatcaagcccaccca 
Occludin NM_008756 gcctaaactacccttatagt gctcttgggtctgtatatcc 
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CHAPTER 4 MEndoT plays a functional role in cardiac repair 
 
 
Overview 
 
Objective: The goal of this study is to determine the physiological significance of MEndoT 
after acute ischemic cardiac injury.  After demonstrating that p53 regulates MEndoT ex vivo, 
we use gain and loss of function approaches in vivo to determine what effects MEndoT has 
on wound healing and cardiac function after injury. 
Methods and Results:  We utilized p53 based gain and loss of function approaches to 
determine the physiological role of MEndoT after cardiac injury.  By genetic deletion of p53 
in fibroblasts prior to injury, we observed a reduction in MEndoT and a decrease in 
vascularity at the injury border zone.  We also observed a significant decrease in cardiac 
function and increased scarring in mice with p53 deleted prior to injury as compared to mice 
with intact p53.  Conversely, when treated with a p53 activator, RITA, after cardiac injury 
mice showed increased MEndoT and increased vascularity at the site of injury when 
compared to PBS treated control animals.  RITA treated injured animals also showed 
improved cardiac function and reduced scar formation as compared to control animals. 
Conclusions: Here we show that MEndoT plays a significant role in the wound healing 
process after acute cardiac injury.  Inhibition of MEndoT after cardiac injury led to significant 
declines in vascularity and heart function and increased scar formation.  Our observations 
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suggest a novel therapeutic strategy for enhancing cardiac repair after acute ischemic injury 
that can be used to ameliorate decline in post-injury cardiac function and reduce scarring. 
 
Introduction 
 
 Myocardial infarction is the leading cause of morbidity and mortality in the United 
States1.  Revascularization at the site of ischemic cardiac injury is essential to normal 
wound healing.  The return of regulated blood flow delivers necessary oxygen and nutrients 
to surviving cells bordering the site of injury and fosters the proliferation of fibroblasts and 
endothelial cells allowing reparative fibrosis.  Accelerated neovascularization of the injury 
region promotes rapid recovery of the ischemic heart. Current research efforts have focused 
on the use of cellular reprogramming2,3, targeting endothelial cell proliferation to improve 
angiogenesis4, localization of circulating endothelial progenitor cells5,6,7,8 and resident 
cardiac stem cells9,10 to increase the pool of endothelial cells in the injured heart, thereby 
increasing vascularity at the site of injury.  Evaluation of each of these strategies is still 
underway but to date each method has demonstrated improvements in cardiac function after 
injury. 
Given our findings that cardiac fibroblasts can adopt an endothelial fate after injury 
and that the process is mediated by p53 ex vivo, we sought to determine what role MEndoT 
plays in the physiology of wound healing.  Since MEndoT contributes to vascularity after 
injury, we also sought to determine whether improving MEndoT would lead to increased 
neovascularization at the site of injury and improve cardiac function. 
To determine how manipulations of MEndoT would affect vascularity and cardiac 
function we used gain and loss of function approaches.  By deleting p53 prior to injury in 
cardiac fibroblasts we sought to determine what effect loss of MEndoT would have on 
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vascularity at the site of injury and associated cardiac function.  Conversely, using RITA to 
increase p53 levels after injury we sought to determine if increasing MEndoT could improve 
vascularity and provide a therapeutic benefit. 
 
Materials and Methods 
 
Generation of transgenic mice 
All animal experiments were conducted in accordance with the University of North Carolina 
Institutional Animal Care and Use Committee (IACUC) guidelines.  Collagen1a2-
CreERT:R26RtdTomato mice were obtained by breeding Collagen1a2-CreERT mice with 
R26RtdTomato mice.  Collagen1a2-CreERT:R26RtdTomato:p53CKO mice were obtained by 
crossing and backcrossing Collagen1a2-CreERT:R26RtdTomato mice with p53fl/fl mice11.  
Genetic labeling or genetic labeling and deletion of p53 was achieved by intraperitoneal 
injection of 8-10 week old Collagen1a2-CreERT:R26RtdTomato or Collagen1a2-
CreERT:R26RtdTomato:p53CKO mice, respectively, with1mg tamoxifen (Sigma) 
intraperitoneally daily for 10 days.  5 days after cessation of tamoxifen the mice either 
underwent ischemia reperfusion or sham injury. 
Cardiac injury model 
Sham or ischemia reperfusion injury was performed as previously described on page 18. 
RITA and PBS treatment after injury 
Injured animals were treated with 0.3mg/kg RITA or PBS once daily for 3 to 7 days 
beginning 24 hours after injury with the number of days of injection depending on the time-
point for heart harvest. 
Immunofluorescent staining , confocal imaging, and quantitation 
Frozen sections (7µm thick) were prepared from hearts isolated 3, 7, or 14 days after injury 
from ischemia reperfusion or sham injured mice.  Sections were stained, imaged and 
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quantitated as described on page 19 with the exception that the primary antibodies used 
were VECAD and p53 (Abcam).  The total number of VECAD positive cells per microscopic 
field were counted using ImageJ software (NIH). 
Echocardiography 
Mice were preconditioned to conscious restraint 5 minutes daily for the 3 days preceding the 
echocardiographic procedure.  Prior to echocardiography, the hair over the anterior chest 
was removed using depilation cream, warmed, and Aquasonic gel applied.  Conscious mice 
were held firmly by hand for the duration of the procedure (5-10 minutes).  The probe was 
positioned over the chest in a parasternal position.  Parasternal long axis B- and M-mode 
images were recorded.  Analysis of echocardiograms was performed using Vevo software 
(FujiFilm). 
Masson’s Trichrome staining and fibrotic area measurement 
Masson’s Trichrome staining was performed as described12 on cardiac sections prepared 7 
or 14 days after injury.  The measurement of fibrotic area was performed using ImageJ 
software (NIH).  The percentage of fibrotic area within the left ventricle was calculated by 
dividing the fibrotic area within the left ventricle by the total area of the left ventricle. 
 
Results 
 
To determine whether p53 regulates MEndoT in vivo, we crossed and back-crossed Col1a2-
CreERT:R26RtdTomato mice with mice that have both p53 alleles floxed.  Progeny mice, 
Col1a2-CreERT:R26RtdTomato:p53fl/fl, at 8-10 weeks of age were given tamoxifen daily for 10 
days to generate mice with fibroblasts deficient in p53, henceforth referred to as Col1a2-
CreERT:R26RtdTomato:p53CKO mice.  The presence of the tdTomato reporter enables us to 
label fibroblasts that are deficient in p53.  At 8-10 weeks of age, these mice received 
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intraperitoneal injection of tamoxifen for 10 days and 5 days after the cessation of tamoxifen 
they underwent ischemia reperfusion or sham injury.  3 days after injury the hearts were 
harvested, sectioned and immunostained for p53 as were their counterparts with intact p53 
(Figure 4.1a-b).  We observed that after injury, Col1a2-CreERT:R26RtdTomato mice with intact 
p53 had a 6±0.64 fold increase (mean±S.E.M.) in p53 expression at the injury border zone 
as compared to mice undergoing sham injury.  However, in mice with p53 deleted prior to 
injury p53 expression did not increase significantly as compared to sham injured animals 
with intact p53 (1.25±0.42 fold (mean±S.E.M.), p=0.23) (Figure 4.1c).  This confirmed that 
p53 was effectively deleted in our p53 CKO model system.   
 To further understand whether p53 deletion would inhibit MEndoT, as we observed in 
our ex vivo model system, we immunostained cardiac sections prepared 3 days after injury 
and found that the percentage of labeled cardiac fibroblasts in Col1a2-
CreERT:R26RtdTomato:p53CKO mice that underwent MEndoT at the injury border zone was 
decreased by 57% as compared to Col1a2-CreERT:R26RtdTomato mice with intact p53 (Figure 
4.2a-c).  We also observed that the total number of VECAD positive endothelial cells at the 
injury border zone was reduced by approximately 41%.   
 Since increased vascular density after cardiac injury is associated with improved 
heart function and reduced scarring we next sought to determine whether the decrease in 
vascularity associated with reduced MEndoT had a negative effect on cardiac function after 
injury.  We performed echocardiographic analysis prior to and 7 days after cardiac injury in 
Col1a2-CreERT:R26RtdTomato:p53CKO and Col1a2-CreERT:R26RtdTomato mice with intact 
p53.  We found that fractional shortening and ejection fraction was significantly reduced 7 
days after injury in Col1a2-CreERT:R26RtdTomato:p53CKO mice as compared to Col1a2-
CreERT:R26RtdTomato mice with intact p53 (Figure 4.3a-b).  We also compared the extent of 
cardiac scarring 14 days after injury by staining cardiac sections with Masson’s Trichrome.  
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We found that the fibrotic area as a percentage of left ventricular area was significantly 
increased in Col1a2-CreERT:R26RtdTomato:p53CKO mice compared to controls (Figure 4.3c-
d). 
   Since the loss of p53 led to a reduction in MEndoT, decrease in vascularity at the 
border zone, decline in heart function and increased scarring, we next sought to determine 
whether increasing p53 levels after injury would have the opposite effect.  To do so, we 
injected Col1a2-CreERT:R26RtdTomato mice with either 0.3mg/kg RITA, a p53 activator, or 
PBS beginning 24 hours after injury.  The hearts were harvested 3 days after injury, 
sectioned and immunostained for p53.  We observed that p53 expression in labeled cardiac 
fibroblasts was increased by 13±0.8 fold in RITA treated ischemia reperfusion injured 
animals as compared to sham injured animals.  This was more than double the p53 
expression in cardiac fibroblasts of PBS treated Col1a2-CreERT:R26RtdTomato mice, which 
was approximately 6 fold more than sham injury (Figure 4.4).   
 To determine the effect of increased p53 expression at the injury border zone on 
MEndoT, we immunostained cardiac sections isolated 3 days after injury in RITA and PBS 
treated Col1a2-CreERT:R26RtdTomato mice for VECAD.  We found that the percentage of 
cardiac fibroblasts expressing the endothelial marker were increased to 51±4% in RITA 
treated animals as compared to 35±3% in PBS treated animals (mean±S.E.M.).  We also 
found that the total number of VECAD positive endothelial cells at the injury border zone 
was significantly increased (Figure 4.5).   
 To understand whether increased MEndoT and vascularity had an effect on scarring 
and heart function, we utilized Masson’s Trichrome staining and echocardiography 
respectively.  We compared fibrosis in sections prepared from hearts isolated 7 days after 
injury in RITA and PBS treated animals.  We found that the percentage of left ventricular 
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scarring was reduced from 39±4% in PBS treated animals to 10±5% in RITA treated animals 
(mean±S.E.M.).  This represents an approximately 75% decrease in the amount of fibrosis 
(Figure 4.6a-b).  We compared echocardiographic measurements of fractional shortening 
and ejection fraction prior to and 7 days after injury and found that in RITA treated animals 
both measures were significantly improved as compared to PBS treatment (Figure 4.6c-d).   
 To demonstrate that the increased MEndoT observed after administration of RITA 
was dependent upon p53 in cardiac fibroblasts, we injected RITA into tamoxifen treated 
Col1a2-CreERT:R26RtdTomato:p53CKO mice after cardiac injury and observed that the ability 
of RITA to enhance MEndoT was significantly attenuated.  The amount of MEndoT 
observed was not statistically different than that observed in tamoxifen treated Col1a2-
CreERT:R26RtdTomato:p53CKO mice not treated with RITA (Figure 4.7), demonstrating that 
RITA enhanced MEndoT primarily occurs through the activation of p53 in cardiac fibroblasts. 
  
Discussion 
 
 Using both gain and loss of function approaches we demonstrated in vivo that 
MEndoT is a p53 mediated process after acute cardiac injury.  We further demonstrated that 
MEndoT plays a functional role in the physiology of wound healing.  By reducing MEndoT by 
genetically deleting p53 in fibroblasts prior to injury, we observed reduced post infarct 
vascularity at the border zone, increased scarring and a decline in heart function.  However, 
when we increased MEndoT using the p53 activator RITA, we found just the opposite effect.  
Taken together, our findings indicate that MEndoT takes place after cardiac injury and is 
mediated by p53.  Further, we have discovered that modulation of p53 levels after cardiac 
injury and subsequent increases in MEndoT can significantly enhance cardiac function.  
Given the previously established link between improved post-infarct angiogenesis and 
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improvements in heart function and scarring, it is not surprising that increases in vascularity 
attributed to MEndoT could enhance cardiac function and reduce scarring after injury. 
While our observations do not exclude the possibility that perturbations of other 
aspects of p53 mediated biology may lead to adverse effects on post-injury wound repair 
and cardiac function, it is also not surprising that given the critical role of neovascularization 
after ischemic injury that a disruption of MEndoT would lead to decreased vascular density 
and diminished heart function. 
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Figure 4.1 Genetic deletion of p53 reduces p53 expression in cardiac fibroblasts. 
 
(a-b) Immunostaining of p53 in cardiac sections prepared from (a) sham and (b) ischemia 
reperfusion injured Col1a2-CreERT:R26RtdTomato or Col1a2-CreERT:R26RtdTomato:p53CKO 
mice 3 days after injury (arrowheads show expression of p53 in labeled cardiac fibroblasts, 
n=4, scale bar = 10µm) (c) Quantitation of p53 expression levels relative to sham injured 
Col1a2-CreERT:R26RtdTomato mice (p<0.005, n=4). 
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Figure 4.2 Genetic deletion of p53 in cardiac fibroblasts leads to a reduction in 
MEndoT and fewer endothelial cells at the border zone of injury. 
 
(a-b) Immunostaining of VECAD in cardiac sections prepared from (a) sham and (b) 
ischemia reperfusion injured Col1a2-CreERT:R26RtdTomato or Col1a2-
CreERT:R26RtdTomato:p53CKO mice (arrowheads show expression of VECAD in labeled 
cardiac fibroblasts, n=4, scale bar = 10µm) (c) Quantitation of the percentage of labeled 
cardiac fibroblasts expressing VECAD (*p<0.005, n=4).  (d) Comparison of the total number 
of VECAD expressing cells per high power microscopic field in sham and ischemia 
reperfusion injured Col1a2-CreERT:R26RtdTomato or Col1a2-CreERT:R26RtdTomato:p53CKO 
mice (* p<0.005, n=5). 
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Figure 4.3 Inhibition of MEndoT leads to reduced heart function and increased 
scarring after acute cardiac injury. 
 
(a-b) Echocardiographic measurement of (a) fractional shortening and (b) ejection fraction 
prior to and 7 days after ischemia reperfusion injury in Col1a2-CreERT:R26RtdTomato or 
Col1a2-CreERT:R26RtdTomato:p53CKO mice (* p<0.05, n=9 for Col1a2-CreERT:R26RtdTomato 
mice and n=8 for Col1a2-CreERT:R26RtdTomato:p53CKO mice). (c) Masson’s Trichrome 
staining of heart sections prepared from Col1a2-CreERT:R26RtdTomato or Col1a2-
CreERT:R26RtdTomato:p53CKO mice 14 days after ischemia reperfusion injury (arrowheads 
indicate fibrotic area (blue), n=4). (d) Quantitation of the fibrotic area as a percentage of the 
left ventricular area (* p<0.05, n=4). 
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Figure 4.4 RITA treatment after acute cardiac injury leads to increased p53 expression 
in cardiac fibroblasts. 
 
(a-b) Immunostaining of p53 in cardiac sections prepared 3 days after (a) sham or (b) 
ischemia reperfusion injury in PBS or RITA treated Col1a2-CreERT:R26RtdTomato mice 
(arrowheads show expression of p53 in labeled cardiac fibroblasts, n=4, scale bar = 10µm) 
(c) Quantitation of p53 expression levels relative to PBS treated sham injured Col1a2-
CreERT:R26RtdTomato mice (p<0.005, n=4). 
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Figure 4.5 RITA treatment after cardiac injury increases MEndoT and vascularity at 
the site of injury. 
 
(a-b) Immunostaining of VECAD in cardiac sections prepared 3 days after (a) sham and (b) 
ischemia reperfusion injury in PBS or RITA treated Col1a2-CreERT:R26RtdTomato mice 
(arrowheads show expression of VECAD in labeled cardiac fibroblasts, n=4, scale bar = 
10µm) (c) Quantitation of the percentage of labeled cardiac fibroblasts expressing VECAD 
(*p<0.05, n=4).  (d) Comparison of the total number of VECAD expressing cells per high 
power microscopic field in sham and ischemia reperfusion injured PBS or RITA treated 
Col1a2-CreERT:R26RtdTomato mice (* p<0.05, n=4). 
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Figure 4.6 Improved vascularity after RITA treatment is associated with reduced scar 
formation and improved cardiac function. 
 
(a) Masson’s Trichrome staining of heart sections prepared from PBS and RITA treated 
Col1a2-CreERT:R26RtdTomato mice 7 days after ischemia reperfusion injury (arrowheads 
indicate fibrotic area (blue), n=4). (b) Quantitation of the fibrotic area as a percentage of the 
left ventricular area (* p<0.05, n=4). (c-d) Echocardiographic assessment of (c) fractional 
shortening and (d) ejection fraction prior to and 7 days after ischemia reperfusion injury in 
PBS or RITA treated Col1a2-CreERT:R26RtdTomato mice (* p<0.05, n=8).  
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Figure 4.7 RITA treatment in p53CKO mice does not significantly improve MEndoT. 
 
(a-d) Immunostaining for VECAD in heart sections prepared 3 days after ischemia 
reperfusion injury in (a) Col1a2-CreERT:R26RtdTomato, (b) Col1a2-CreERT:R26RtdTomato + 
RITA, (c) Col1a2-CreERT:R26RtdTomato:p53CKO + RITA or (d) Col1a2-
CreERT:R26RtdTomato:p53CKO + PBS mice. (e) Quantitation of MEndoT percentage by 
genotype and treatment listed (* p<0.05, n.s. = not significant, n=4 per group). 
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CHAPTER 5 Conclusions and Perspectives 
 
Summary of Findings 
 
In this dissertation I have described a novel phenomenon where fibroblasts undergo 
Mesenchymal-to-Endothelial Transition (MEndoT) in response to acute ischemic injury and 
contribute to vasculogenesis and the revascularization of the injured myocardium.  In 
Chapter 2 I described the use of fate mapping techniques in the determination that cardiac 
fibroblasts at the injury border zone express endothelium-specific markers and integrate into 
the vasculature.  To date, this phenomenon has not been described either during 
development or after injury in any organ system.  In Chapter 3 I describe an ex vivo model 
system of cellular stress that is able to recapitulate the MEndoT seen in vivo.  Further, I 
describe how p53, a key cell cycle regulator, regulates MEndoT.  This finding expands our 
burgeoning understanding of how p53 mediates cellular phenotype conversion.  In Chapter 
4 I demonstrate the physiological significance of MEndoT in wound healing.  By 
manipulating p53 and thereby MEndoT, I show that increasing MEndoT leads to increased 
vascularity at the site of injury and improved cardiac function with reduced scarring.   
Limitations 
 While these observations are novel and stress the potential therapeutic implications 
of MEndoT they also come with a number of caveats, some of which will hereafter be 
described.  
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Murine model 
As previously described, the research presented utilized a Collagen1a2-CreERT 
based labeling system.  While we validated the specificity and labeling efficiency of the 
model, there are some potential challenges which could affect the utility of our findings.  
First, as previously described, there are no known markers that are truly specific to 
fibroblasts.  While we sought to validate the system using Thy1 expression characteristic of 
fibroblasts, there are several other fibroblast markers that could have been used to confirm 
that the labeled cells are fibroblasts.  This would have been useful since Collagen1a2 has 
been demonstrated to be expressed in some other cells1.  Confirmation of the fibroblast 
expression profile could have been achieved by assessing the expression of other targets in 
the labeled cells such as Fsp1, DDR2, or Vimentin using flow cytometry, immunostaining, or 
both.  Secondly, the observations could have been corroborated using another fibroblast 
marker Cre.  As an example, in early work we utilized a non-inducible Fsp1-Cre in in vivo 
and ex vivo model systems to confirm the results, though those results were not presented. 
Another potential limitation to the existing Col1a2-CreERT model was the efficiency 
of the Cre recombinase both during labeling and p53 gene deletion.  After tamoxifen 
injection, we observed that approximately 70% of isolated fibroblasts were labeled.  With 
another Cre line or potentially with an altered tamoxifen administration regime in the Col1a2-
CreERT model, it is possible that the labeling efficiency could have been improved which 
may have provided a more accurate measurement of the percentage of cells undergoing 
MEndoT.  Further, after p53 deletion we still observed p53 expression in labeled fibroblasts 
though expression was reduced by approximately 50%.  With an improved model system, it 
may have been possible to more fully ablate p53 and its expression to obtain a closer 
approximation of how the presumably total loss of MEndoT would affect wound healing.  
While we could have used a global p53 knock-out mouse model to achieve similar results, 
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we chose to use the less efficient conditional knock-out system because it was less likely to 
alter the mouse physiology (i.e. with spontaneous tumor formation) and provide a closer 
view of how MEndoT affects wound healing under normal physiological conditions. 
Another more general limitation of working in a murine model is the caveat that 
observations made in one mouse strain may not be reproducible across strains or, more 
importantly, across species to humans.  One of the ultimate goals of this research is to 
identify therapeutics for human patients.  Given the prevalence of myocardial infarction and 
the burden of the disease on the human population and the healthcare system, we would 
like to find a treatment to improve the outcome of human patients, not mice.   
 
Unexpected and off-target effects of p53 manipulation 
 As previously stated, p53 is part of the complex and highly regulated MAPK pathway.  
Another limitation of the work described is that perturbations in p53 biology can have 
unexpected and off-target effects, either within the affected cells or in neighboring cells.   
 As a specific example, in the simplified context of our ex vivo work, we showed that 
manipulation of p53 had very direct effects on the adoption of endothelial traits during 
MEndoT.  However, in the body cells operate in a complex milieu replete with various 
extracellular signals.  It is likely that the direct effects we demonstrated in the ex vivo model 
may be mitigated (or enhanced) by other factors at the site of injury.  The increased 
complexity of the in vivo model may have a direct effect on the presented results.  As an 
example, while deletion of p53 prior to injury did not have an apparent effect on heart 
function, after injury, heart function was decreased.  While we attribute that result in the 
context of other findings on the effects of fibroblasts on vascularity in wound healing2,3,4, it is 
possible that p53 deletion in fibroblasts could have an unexpected and previously unknown 
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role in maintaining heart function after injury.  Similarly and perhaps more directly, deletion 
of p53, a key cell cycle checkpoint, could have led to the increased proliferation of 
fibroblasts, which in turn led to the increased scarring observed as well as potentially 
adverse consequences for heart function. 
 While we used gain and loss of function approaches to strengthen our claims that 
changes in post-injury vascularity associated with MEndoT can lead to reduced scarring and 
improved cardiac function after injury, it is also possible that RITA treatment after injury 
functionally reduced the proliferation of fibroblasts and the reduced scarring was a 
consequence.  That reduction in scarring may also have led to improved heart function 
through an unknown mechanism. 
 Alternatively, RITA treatment could have had off-target effects that led to 
improvements in heart function.  As an example, the RITA administered systemically 1-3 
days after injury could locally have affected the biology of a number of different cell types 
(i.e. neutrophils, macrophages, endothelial cells, cardiomyocytes) at the site of injury or 
even other organs such as the kidneys that regulate blood pressure.  We cannot exclude 
that off target effects may have played a role in the improvements in heart function observed 
after RITA treatment.  Until the technology used to activate p53 can be restricted to 
fibroblasts, it is difficult to perfectly attribute all of the changes in heart function and wound 
healing observed solely to MEndoT. 
 
Analysis of cells in aggregate 
 One of the other limitations of this work is that much of the analysis was performed 
on an aggregate pool of cells.  While we observed that approximately 30% of labeled 
fibroblasts at the border zone were able to adopt an endothelial phenotype after injury, it 
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begs the question of why the other 70% of labeled fibroblasts, ostensibly exposed to the 
same cellular context, did not.  The ex vivo work that determined the mechanism governing 
MEndoT was described using techniques that treat cells in a pool.  However, to better 
understand the regulation of MEndoT, a single cell based approach may offer additional 
benefits.  Current limitations on the use of high-throughput single cell analysis effectively 
reduce the ability to study MEndoT on large numbers of individual cells.  In the future, as 
better and more affordable analysis techniques become available, it may be interesting to 
study and characterize cell subpopulations and understand why, or why not, they undergo 
MEndoT. 
 
Future Directions 
 
The discovery of MEndoT and the elucidation of its mechanical underpinnings 
presented in this dissertation are by no means an exhaustive study of all aspects of this 
form of cellular transition.  There are several key questions yet to be addressed in order to 
more fully understand the process of MEndoT and its implications.  In this section, a series 
questions addressing other associated areas of scientific exploration are proposed. 
Does MEndoT occur in other organ systems? 
 During our research we demonstrate that MEndoT occurs after ischemic cardiac 
injury and contributes to neovascularization at the injury border zone.  One question we did 
not address was whether MEndoT occurs in the wound healing process in other organ 
systems.  As an example, during granulation tissue formation in the wound healing response 
of the skin, local fibroblasts and endothelial cells have been shown to communicate to 
coordinate scar formation in a fashion similar to what takes place in the heart.  It may be 
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possible that when exposed to alternate forms of cellular stress local fibroblasts in other 
parts of the body may adopt an endothelial phenotype.  In the case of skin injury, exposure 
of fibroblasts to the outside environment may lead to MEndoT as p53 becomes upregulated.  
Using the same murine model, injury to other organ systems could be studied to determine 
whether MEndoT occurs in other parts of the body. 
  The idea of MEndoT in response to injury could also be extended to cancer.  During 
cancer, tumor growth often leads to local tissue hypoxia5,6.  Given the pervasive nature of 
fibroblasts in the body, it is also possible that local fibroblasts, when exposed to hypoxic 
conditions similar to those after ischemic cardiac injury, could adopt an endothelial 
phenotype and contribute to the vasculature supplying the growing tumor.  This may even 
provide an alternative explanation as to why anti-angiogenic therapies have limited success 
in the treatment of cancers7,8,9,10. 
The concept of MEndoT also need not be limited to injury.  While it has not been 
formally described, it is possible that MEndoT may also occur during development.  Unlike 
MET, which has been shown to take place during kidney formation11,12, MEndoT has not 
been expressly shown.  After demonstrating that MEndoT can take place after injury, it may 
further our understanding of biology to determine whether it also takes place in during 
development. 
 
Can fibroblasts adopt other fates? 
 We show that cardiac fibroblasts can adopt an endothelial fate after ischemic injury.  
That leads to the question of whether fibroblasts can adopt other fates as well.  While not 
covered in the context of this work, we can address that question in a limited way based on 
other studies we have conducted.  In my earlier work, I observed that cardiac fibroblasts can 
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also adopt an epithelial fate in response to ischemic cardiac injury.  This study was 
proposed to, and funded by, the American Heart Association in my pre-doctoral fellowship 
(Role of Mesenchymal-to-Epithelial Transition in Cardiac Repair - Award #11PRE7720016).  
Preliminary data even suggest that the MET that takes place in the heart is mediated by a 
similar stress response mechanism.  Whether the subset of fibroblasts undergoing MET is 
the same as the subset undergoing MEndoT has not been determined.  However, it is 
entirely possible that cardiac fibroblasts can adopt more than one phenotype in response to 
injury. 
 Along those lines, while in our work we demonstrated that fibroblasts adopt an 
endothelial phenotype, we did not perform an exhaustive characterization of other potential 
phenotypes they may also adopt.  As an example, we did not determine whether these cells 
adopt a lymphatic phenotype, which would be closely related to an endothelial phenotype.  
Again, the tools to perform the study exist and it would be interesting to determine whether 
such other changes occur. 
 
How does phenotypic conversion occur during MEndoT? 
 Another issue that was not exhaustively addressed during this study was how 
fibroblasts adopt an endothelial fate.  It has been previously shown that fibroblasts adopt a 
proto-myofibroblast fate prior to becoming full-fledged myofibroblasts13.  Do cardiac 
fibroblasts adopt an intermediary state during MEndoT before becoming endothelial-like 
cells or do they transition directly from one fate to another?    
 If cardiac fibroblasts adopt an intermediate state, do they regress to a multi-potent 
precursor prior to redifferentiation?  If that were the case, would it be possible that since a 
subset of endothelial cells in the heart are also derived from a Wt1 lineage14,15 that post-
injury fibroblasts revert and then adopt the endothelial phenotype along a different branch of 
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the same Wt1 lineage?  To a very limited extent, we have preliminary data that suggest that 
fibroblasts that expressed Wt1 during development are capable of adopting an endothelial 
phenotype.  It would be an interesting line of questioning to determine whether the transition 
was Wt1 lineage specific or not. 
 Another question that was not addressed during our research was about phenotypic 
reversal.  We showed that when cardiac fibroblasts are exposed to cellular stress a subset 
will adopt an endothelial phenotype.  However, we did not determine whether once the 
stress was reduced or eliminated whether the MEndoT cells would revert to fibroblasts.  
Given that the change is p53 mediated, it is possible that once the stress, and therefore the 
p53 signaling, is removed the cells could revert.  This would be a difficult question to 
address in vivo partly because of the labeling strategy necessary and because during the 
scar maturation process most of the fibroblasts and endothelial cells propagated during 
granulation tissue formation undergo apoptosis16. 
 
How does p53 specifically regulate MEndoT? 
 We demonstrate, through gain and loss of function approaches, that MEndoT is 
mediated by p53.  However, in our study of the phenomenon of MEndoT, we did not 
exhaustively study how p53 regulates the process.  There are a few key questions that 
would help our understanding of p53 based regulation.   
First, since p53 has been linked to the cellular stress response through the MAPK 
pathway, it would be interesting to determine what upstream regulators trigger p53 activity.  
As an example, could TGF-β, which factors prominently in the fibrotic response, activate p53 
activity?  Could p38 and JNK, which are directly upstream of p53, play a role?  Each of 
these molecular targets has pharmacological activators and inhibitors akin to Pifithrin-α and 
RITA, respectively, that could be used to test potential interactions. 
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In addition to upstream regulation, the question can also be asked whether p53 acts 
directly as a transcription factor on endothelial gene targets or works through an 
intermediary.  To date, we have preliminary data that favors the former hypothesis.  Using 
Chromatin Immunoprecipitation (ChIP), our collaborators have shown that p53 is enriched in 
the promoter regions of several endothelial genes after serum starvation which suggests 
that p53 gene regulation is direct.  Still, the direct regulation has not been conclusively 
proven. 
Another potential source of p53 regulation is through post-translational modification.  
p53 has been described as having as many as 50 sites for post-translational modification17.  
Any one or a combination of sites may regulate the process of MEndoT.  Existing tools such 
as mass spectrometry could be used to determine whether post-translational modification of 
p53 plays a role in MEndoT.  Finding pertinent post-translational modifications could allow 
for mutational screens for gain and loss of function studies as well as allowing drug 
development for specific activation of MEndoT. 
Upregulation of p53 has also been linked to exist from the cell cycle18,19.  It would be 
interesting to determine whether the p53 activation that takes place during MEndoT pushes 
the cell towards senescence and drives them down a specific alternative lineage. 
 
How do MEndoT cells interact with neighboring cells after injury? 
 Given that most fibroblasts and endothelial cells undergo apoptosis as the fibrotic 
scar matures16, it leads us to question what the longer term fate of MEndoT cells are or if 
their function is served after a brief time.  If that is the case, then in addition to contributing 
to the restoration of blood flow to the injured area, are there any other interactions between 
MEndoT cells and the neighboring cells at the injury border zone?  We did not explore these 
interactions but, as described in Chapter 1, fibroblasts interact closely with macrophages, 
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endothelial cells and even cardiomyocytes.  Are these other cell types affected by MEndoT 
cells? 
 We also observed that the number of endothelial cells at the site of injury was 
increased when MEndoT was increased.  Could it be that MEndoT promotes the 
proliferation of endothelial cells or could the proliferation be explained as a by-product of 
RITA treatment?  These are all interesting questions that could be addressed during the 
continued study of MEndoT. 
 
Are there potential therapeutic applications of MEndoT in the treatment of acute ischemic 
cardiac injury in Humans? 
The discovery of MEndoT is a novel finding with therapeutic implications in the 
treatment of ischemic cardiac disease.  As described in Chapter 4, by improving vascularity 
at the site of injury the adverse effects of cardiac injury were effectively reduced.  While 
several methods of improving vascularity after cardiac injury have been explored, many 
carry with them potential drawbacks.  As an example, cellular reprogramming of fibroblasts 
into endothelial cells using exogenous transcription factors carries the potential dangers of 
off-target reprogramming of other cells, cellular dis-regulation and tumor formation20,21.  
Another example, using the explantation, expansion in culture, and reintroduction of cardiac 
stem or vascular progenitor cells is somewhat invasive, time-consuming, and inefficient22,23.  
Manipulating MEndoT represents a potential step forward in neovascularization targeted 
treatment of ischemic cardiac injury without some of the drawbacks associated with other 
models.  Specifically, RITA based treatment is non-invasive and can be administered readily 
after injury.  Further, while there is potential for off-target effects, p53 targeted treatments 
like RITA are currently in clinical trials for the treatment of cancer24.  Based on the outcome 
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of those studies, it may be found that RITA treatment has minimal off-target effects and 
could be a prime target for clinical studies.   
 
Conclusions 
As described in this dissertation, we have identified Mesenchymal-to-Endothelial 
Transition (MEndoT) as a previously undescribed phenomenon in the progression of wound 
healing after acute ischemic cardiac injury.  Our findings demonstrate that cardiac fibroblasts 
contribute to neovascularization at the site of injury and that manipulation of MEndoT is a 
potentially novel therapeutic in the treatment of myocardial infarction.  Moreover, our 
findings increase our understanding of the roles of fibroblasts in guiding the progression of 
wound healing and scarring and suggest that further study of the process may also 
contribute to the broader understanding of cellular plasticity and its regulation.  
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